Compounded GLP-1s: What the FDA Enforcement Action Reveals

The FDA's Compounded GLP-1 Enforcement Action: Clinical and Regulatory Context

The FDA's recent enforcement action against telehealth companies marketing compounded GLP-1 receptor agonists represents a critical inflection point in the peptide and hormone optimization space. This isn't about whether compounded medications work—it's about claims made without pharmacokinetic validation, stability data, or bioequivalence evidence.

What Triggered the Enforcement

The core issue: telehealth platforms were making efficacy claims for compounded semaglutide, tirzepatide, and related GLP-1 agonists without establishing that their formulations were pharmaceutically equivalent to FDA-approved counterparts (Ozempic, Mounjaro, Zepbound). Many marketed "pharmaceutical-grade" or "medical-grade" compounded versions with identical dosing to branded products, implying bioavailability parity that was never demonstrated through comparative studies.

Specifically, the FDA identified misleading advertising suggesting compounded formulations deliver the same clinical outcomes as FDA-approved versions. This matters because:

• Stability is formulation-specific. A compounded semaglutide suspension at 5 mg/mL may have different degradation kinetics than the branded weekly injection at 0.25–2.4 mg/dose.
• Bioavailability assumptions are unfounded. Compounding pharmacies don't routinely conduct in vivo bioavailability studies comparing their products to reference standards.
• Potency assurance varies. While some compounding pharmacies maintain rigorous quality control (third-party HPLC testing), regulatory oversight is inconsistent across states.

The Pharmacological Reality

GLP-1 receptor agonists work via a well-characterized mechanism: binding to GLP-1 receptors on pancreatic beta cells, enteroendocrine cells, and hypothalamic neurons. This triggers glucose-dependent insulin secretion, delays gastric emptying, and promotes satiety signaling.

The active pharmaceutical ingredient—whether semaglutide or tirzepatide—is the same molecule regardless of source. But pharmaceutical formulation profoundly affects pharmacokinetics:

• Subcutaneous depot formulation (Ozempic's agomelastine-based suspension) creates predictable absorption kinetics over 7 days.
• Compounded aqueous solutions may be absorbed more rapidly, reducing the sustained-release benefit.
• Compounded oil-based or modified-release formulations are experimental and lack published pharmacokinetic data in humans.

This distinction is why your prescriber should understand what they're prescribing.

What Physicians and Patients Should Verify

If a patient presents with a compounded GLP-1 prescription, ask:

1. Has the compounding pharmacy published or disclosed stability data? Legitimate compounds should have beyond-use dating supported by real-time or accelerated stability studies (ICH guidelines).

2. What potency assurance exists? HPLC analysis by a third-party lab (not the pharmacy itself) is the minimum standard.

3. Is the formulation bioequivalent to the reference product? If the pharmacy claims "equivalent efficacy," they should cite comparative pharmacokinetic data. Most won't have it.

4. What's the legal status in your state? Compounding pharmacies operate under state oversight. Some states allow "office-use" compounding; others don't. The FDA's authority is limited to interstate commerce.

The Regulatory Framework

Under the Pharmacy Compounding Quality Act (2023), compounding pharmacies can legally compound GLP-1 agonists from bulk powder sources—if they comply with USP monographs, use FDA-approved ingredients, and don't market them as therapeutically equivalent to brand-name drugs.

Where telehealth companies erred: claiming equivalent outcomes without evidence, marketing "pharmaceutical-grade" quality without third-party validation, and offering tiered dosing protocols based on marketing rather than clinical pharmacology.

Baseline Blood Work Before GLP-1 Therapy

Regardless of formulation source, baseline labs are non-negotiable:

• Fasting glucose, insulin, HOMA-IR (insulin resistance index)
• HbA1c (3-month glucose average; <5.7% is normal)
• Comprehensive metabolic panel: AST, ALT, creatinine (kidney function), electrolytes
• Lipid panel (GLP-1 agonists improve lipid profiles, but baseline matters)
• TSH, free T4 (rule out undiagnosed thyroid disease; GLP-1s don't cause dysfunction but can reveal subclinical hypothyroidism)
• Calcitonin (rules out medullary thyroid carcinoma history—absolute contraindication)
• Amylase, lipase (baseline for pancreatitis risk assessment)
• Albumin (indicator of nutritional status; important when reducing intake)

Repeat labs every 3 months during titration, then quarterly during stable therapy.

GLP-1 Efficacy Across Formulation Types

Clinical data support compounded GLP-1 agonists when properly formulated, but heterogeneity exists:

• SUSTAIN trials (semaglutide): 13–17% HbA1c reductions in type 2 diabetes with branded weekly injections.
• ZEPBOUND/MOUNJARO trials (tirzepatide): 16–22% body weight reductions in obesity trials.
• Compounded data: Sparse. Most "evidence" is anecdotal or derived from off-label use protocols not published in peer-reviewed journals.

The FDA enforcement sends a clear message: marketing compounded formulations as clinically equivalent without trial data violates advertising law. Physicians should demand transparency from their compounding sources.

Synergistic Supplementation with GLP-1 Therapy

GLP-1 agonists induce weight loss partially through appetite suppression, which reduces caloric intake. This creates micronutrient risk:

• Vitamin B12: GLP-1s don't impair absorption, but reduced food intake may. Baseline serum B12 and methylmalonic acid should be checked. Consider methylcobalamin supplementation (1000 mcg weekly) or cyanocobalamin (1000 mcg IM monthly).
• Magnesium glycinate: 300–400 mg daily supports insulin sensitivity and mitigates potential constipation (common with GLP-1s).
• Zinc: 20–30 mg daily (separate from other minerals) supports immune function and metabolic health during weight loss.
• Omega-3 (EPA/DHA): 2000–3000 mg daily improves lipid profiles synergistically with GLP-1 therapy.
• NAC (N-acetylcysteine): 600–1200 mg daily supports liver health and may reduce GLP-1-related nausea via glutathione repletion.

Bottom Line

Compounded GLP-1 agonists are legally permissible but require rigorous scrutiny. The FDA enforcement action highlights the distinction between legal compounding and clinically validated compounding. Before prescribing or using any GLP-1 formulation, verify:

1. Stability and potency data
2. Baseline metabolic labs
3. Clear pharmacokinetic expectations
4. Quarterly monitoring protocols
5. Supportive micronutrient supplementation

The molecule semaglutide or tirzepatide works. The formulation determines reliability. Demand transparency from your compounding source—or stick with FDA-approved brands where quality is guaranteed.

Disclaimer: This content is for educational purposes only and does not constitute medical advice.